SEP 18·SEC EDGARHigh
Shen Ching Hang purchased $5.0M of CV (indirect holdings)
Shen Ching Hang purchased 878,734 indirectly-held shares of CapsoVision, Inc (CV) at $5.69 ($5.00M total) on 2026-09-15.
StockNASDAQ · US · USDHealthcare · MEDICAL DEVICES
$CV
CapsoVision, Inc
Price · $CVvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 0
- Bearish
- 1
Insider · 30dAll trades →
- Buys
- $5.0M 1 txs
- Sells
- — 0 txs
Shen Ching Hang1× · $5.0M
10b5-1 share of filings0%
Top stories · $CVMore →
SEP 18·SEC EDGAR 8-K
CapsoVision, Inc (CV): Entry into a Material Definitive Agreement
CapsoVision, Inc (CV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 17, 2026, CapsoVision, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), which provides for the issuance and sale, in a regist
AUG 13·SEC EDGAR 8-K
CapsoVision, Inc (CV): Results of Operations and Financial Condition
CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financia
CV sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CV (CapsoVision, Inc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CV coverage spans insider activity, corporate actions and earnings.
In the last 30 days, CV insiders filed 1 SEC Form 4 transaction — 1 purchase ($5.0M) and no sales. The most active reporter was Shen Ching Hang with 1 filing.
What's driving CV
Large insider purchase may signal confidence and could support price.
The capital raise provides near‑term liquidity for corporate purposes and may dilute existing shareholders.
The filing signals potential near-term dilution risk and incremental funding capacity via an at-the-market equity program.
The EU rollout of an AI-assisted review feature is a commercial expansion catalyst, but the release provides no revenue, pricing, or regulatory clearance details for the US.
This is a routine Form 4 insider purchase with no 10b5-1 plan disclosed; it may modestly support sentiment but is not a fundamental catalyst.
AlphAI scores every news story that mentions CV with an AI model for sentiment and relevance, and aggregates insider trades from CapsoVision, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CV
Score
Shen Ching Hang purchased $5.0M of CV (indirect holdings)
Shen Ching Hang purchased 878,734 indirectly-held shares of CapsoVision, Inc (CV) at $5.69 ($5.00M total) on 2026-09-15.
1 min readCapsoVision, Inc (CV): Entry into a Material Definitive Agreement
CapsoVision, Inc (CV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 17, 2026, CapsoVision, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), which provides for the issuance and sale, in a regist
2 min readCapsoVision, Inc (CV): Results of Operations and Financial Condition
CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financia
3 min readCapsoVision Announces International Launch of AI Highlights
CapsoVision (NASDAQ: CV) said it launched its AI Highlights feature for the CapsoCam Plus capsule endoscopy system in international markets, including the EU. The AI flags suspected clinically relevant frames during standard processing and integrates with CapsoView and CapsoCloud workflows. The update is offered where authorized; it is not cleared by the FDA for US sale.
3 min readHARARI ELIYAHOU ET AL purchased $411K of CV (indirect holdings)
HARARI ELIYAHOU ET AL purchased 61,068 indirectly-held shares of CapsoVision, Inc (CV) at $6.73 ($0.41M total) on 2026-07-17.
2 min readHARARI ELIYAHOU ET AL purchased $495K of CV (indirect holdings)
HARARI ELIYAHOU ET AL purchased 81,300 indirectly-held shares of CapsoVision, Inc (CV) at $6.09 ($0.50M total) on 2026-07-08.
1 min readHARARI ELIYAHOU ET AL purchased $102K of CV (indirect holdings)
HARARI ELIYAHOU ET AL purchased 13,850 indirectly-held shares of CapsoVision, Inc (CV) at $7.35 ($0.10M total) on 2026-06-26.
1 min read
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
CapsoVision (Nasdaq: CV) said it appointed gastroenterology leader David S. Shields, M.D., to its board effective July 1, 2026. Shields has served as a clinical advisor for nearly a decade. He replaces Joanne C. Imperial, who stepped down but will continue as an independent clinical consultant. The company cited upcoming milestones for AI-assisted reading and pipeline studies.
3 min readCapsoVision, Inc (CV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
CapsoVision, Inc (CV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 cv-20260702xex1001.htm EX-10.1 Document Exhibit 10.01 Certain confidential information contained in this document, marked by [* * *], has been omitted pursuant to Item 601 (b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information
3 min readCapsoVision, Inc (CV): Submission of Matters to a Vote of Security Holders
CapsoVision, Inc (CV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cv-20260611 FALSE 0001378325 0001378325 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 8-K _________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
2 min read